Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
-  To assess the effect of a long-term treatment by Genotonorm on linear growth in children
 with short stature receiving steroid therapy

 -  To assess the effect of a long term treatment with Genotonorm on bone mineralisation

 -  To assess the effect of a long term treatment with Genotonorm on body composition
This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and
 data collection discrepancies. The decision to terminate was not based on any safety
 concerns.
Inclusion Criteria:

 -  Children with juvenile arthritis or nephrotic syndrome

 -  Before or during puberty

 Exclusion Criteria:

 -  Diabetes Type 1 and 2

 -  Endocrine disease, except well substituted hypothyroidism